GenBio AI: The First Digital Living System
GenBio AI is an AI company headquartered in Silicon Valley with hubs in Paris and the UAE that is developing a new way to understand and program human biology. The company is building AIDO, the AI-Driven Digital Organism, to address a fundamental limitation in traditional biomedical research. Today, most research analyzes DNA, RNA, proteins, cells, and tissues separately. Biology does not function in separate parts. It operates as an interconnected system. GenBio AI aims to decode biology holistically so that therapeutics can be discovered, optimized, and evaluated with greater precision and at unprecedented scale.
The Scientific Challenge
Drug development is slow, expensive, and constrained by fragmented data and siloed methods. Most failures in clinical trials stem from an incomplete understanding of biological systems. By unifying biology into a single computational framework, AIDO allows us to simulate and reason across scales, reducing uncertainty early and enabling more predictive drug design, target selection, and safety modeling.
Technology Overview
AIDO is being built on a multiscale foundation model system trained on a billion-scale integrated biological datasets. It spans DNA, RNA, proteins, structures, interactions, cells, tissues, and organism-level biology.Recent results highlight the scientific progress.
● AIDO Protein-RAG ranks first on ProteinGym.
● AIDO.Cell is selected by the Chan Zuckerberg Initiative as a representative model for the virtual cell.
● Research associated with AIDO shows state-of-the-art performance at multiple biological scales.
This system represents the architecture required to build the world’s first digital organism and unlock programmable biology.
Open Science and Global Momentum
GenBio AI continues to support open and transparent scientific development. Its models have been downloaded more than ten thousand times through Hugging Face and GitHub. The company currently supports more than three hundred datasets and twenty eight fine tuned models.The Foundation Models for Biology Seminar Series continues to attract global leaders in artificial intelligence and the life sciences. Through a combination of open research, partnerships, and community engagement, GenBio AI is helping accelerate scientific innovation across academia, biotechnology, and pharmaceutical research.
Commercial Strategy and Market Opportunity
AIDO enables new business models across the biomedical lifecycle.
● Near term: Model access, APIs, and research collaborations.
● Mid term: Partnerships in drug discovery, target identification, and precision medicine.
● Long term: Proprietary therapeutic programs built on digital-first biology.
With its integrated multiscale foundation model system, GenBio AI is positioned to drive a generational shift in biotechnology. The company sees a path to higher success rates, shorter development cycles, and the creation of new therapeutic modalities powered by computational biology.
For more information and access to GenBio AI scientific publications, please visit https://genbio.ai